{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T18:57:28Z","timestamp":1794769048684,"version":"4.9.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS136524"],"award-info":[{"award-number":["R01NS136524"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejmech.2025.117924","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:39:39Z","timestamp":1751373579000},"page":"117924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Lead optimization of a CHI3L1 inhibitor for Glioblastoma: Enhanced target engagement, pharmacokinetics, and efficacy in 3D spheroid models"],"prefix":"10.1016","volume":"297","author":[{"given":"Baljit","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossam","family":"Nada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longfei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9074-3331","authenticated-orcid":false,"given":"Moustafa T.","family":"Gabr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117924_bib1","series-title":"StatPearls","article-title":"Glioblastoma multiforme","author":"Kanderi","year":"2025"},{"key":"10.1016\/j.ejmech.2025.117924_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105780","article-title":"Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance","volume":"171","author":"Wu","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2025.117924_bib3","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.3390\/ijms25053040","article-title":"Glioblastoma: an update in pathology, molecular mechanisms and biomarkers","volume":"25","author":"Lan","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117924_bib4","unstructured":"What is the average glioblastoma survival rate?, Glioblastoma Research Organization (n.d.). https:\/\/www.gbmresearch.org\/blog\/glioblastoma-survival-rate (accessed May 9, 2025)."},{"key":"10.1016\/j.ejmech.2025.117924_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctarc.2025.100881","article-title":"Unlocking the code: the role of molecular and genetic profiling in revolutionizing glioblastoma treatment","volume":"43","author":"Mansour","year":"2025","journal-title":"Cancer Treatment and Research Communications"},{"key":"10.1016\/j.ejmech.2025.117924_bib6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3390\/cancers14020443","article-title":"Tumor cell infiltration into the brain in glioblastoma: from mechanisms to clinical perspectives","volume":"14","author":"Seker-Polat","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2025.117924_bib7","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1101\/gad.261982.115","article-title":"Cancer stem cells in glioblastoma","volume":"29","author":"Lathia","year":"2015","journal-title":"Genes Dev."},{"key":"10.1016\/j.ejmech.2025.117924_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312654","article-title":"Blood\u2013brain barrier in brain tumors: biology and clinical relevance","volume":"22","author":"Mo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117924_bib9","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.3390\/cancers15072116","article-title":"Mechanisms of resistance and current treatment options for glioblastoma multiforme (GBM)","volume":"15","author":"Yalamarty","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2025.117924_bib10","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1021\/jm00009a010","article-title":"Antitumor imidazotetrazines. 32.1 synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide","volume":"38","author":"Clark","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117924_bib11","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.3390\/curroncol31070296","article-title":"Temozolomide (TMZ) in the treatment of glioblastoma multiforme\u2014A literature review and clinical outcomes","volume":"31","author":"Jezierza\u0144ski","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ejmech.2025.117924_bib12","doi-asserted-by":"crossref","DOI":"10.4137\/CMO.S8503","article-title":"Bevacizumab for the treatment of glioblastoma","volume":"7","author":"Gil-Gil","year":"2013","journal-title":"Clin. Med. Insights Oncol."},{"key":"10.1016\/j.ejmech.2025.117924_bib13","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","article-title":"Temozolomide resistance in glioblastoma multiforme","volume":"3","author":"Lee","year":"2016","journal-title":"Genes & Diseases"},{"key":"10.1016\/j.ejmech.2025.117924_bib14","first-page":"17","article-title":"Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review","volume":"4","author":"Singh","year":"2021","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.ejmech.2025.117924_bib15","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s12672-025-02567-3","article-title":"Glioblastoma multiforme: an updated overview of temozolomide resistance mechanisms and strategies to overcome resistance","volume":"16","author":"Pu","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.ejmech.2025.117924_bib16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy\u2013temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.117924_bib17","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.117924_bib18","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/annonc\/mdy120","article-title":"Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial","volume":"29","author":"Wirsching","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2025.117924_bib19","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1021\/acs.molpharmaceut.4c01227","article-title":"The tumor-derived exosomes enhanced bevacizumab across the blood\u2013brain barrier for antiangiogenesis therapy against glioblastoma","volume":"22","author":"Chu","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2025.117924_bib20","doi-asserted-by":"crossref","first-page":"6602","DOI":"10.1038\/s41598-017-06888-4","article-title":"Overcoming blood brain barrier with a dual purpose temozolomide loaded lactoferrin nanoparticles for combating glioma (SERP-17-12433)","volume":"7","author":"Kumari","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.117924_bib21","unstructured":"S0006295223003179, (n.d.)."},{"key":"10.1016\/j.ejmech.2025.117924_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.116886","article-title":"Natural small molecule thymoquinone increases the chemosensitivity of glioblastoma to temozolomide through inhibiting Wnt\/\u03b2-catenin signaling pathway to downregulate MGMT expression: in vitro and in vivo validation","volume":"236","author":"Bai","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117924_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117411","article-title":"Discovery of a novel wnt inhibitor DK419: reversing temozolomide resistance in glioblastoma by switching off Wnt\/\u03b2-catenin signaling pathway to inhibit MGMT expression","volume":"288","author":"Bai","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117924_bib24","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1021\/acsptsci.4c00085","article-title":"Energy blocker lonidamine reverses nimustine resistance in human glioblastoma cells through energy blockade, redox homeostasis disruption, and O6-Methylguanine-DNA methyltransferase downregulation: in vitro and in vivo validation","volume":"7","author":"Huang","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2025.117924_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116588","article-title":"Novel strategies to overcome chemoresistance in human glioblastoma","volume":"230","author":"Tang","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117924_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2023.103449","article-title":"The dual role of DNA repair protein MGMT in cancer prevention and treatment","volume":"123","author":"Bai","year":"2023","journal-title":"DNA Repair"},{"key":"10.1016\/j.ejmech.2025.117924_bib27","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41416-020-01136-5","article-title":"Tumour treating fields therapy for glioblastoma: current advances and future directions","volume":"124","author":"Rominiyi","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.117924_bib28","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ejmech.2025.117924_bib29","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41582-024-00967-7","article-title":"IDH inhibition in gliomas: from preclinical models to clinical trials","volume":"20","author":"Rud\u00e0","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejmech.2025.117924_bib30","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41416-020-0814-x","article-title":"IDH mutation in glioma: molecular mechanisms and potential therapeutic targets","volume":"122","author":"Han","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.117924_bib31","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.3390\/ijms26083539","article-title":"The prognostic significance of epidermal growth factor receptor amplification and epidermal growth factor receptor variant III mutation in glioblastoma: a systematic review and meta-analysis with implications for targeted therapy","volume":"26","author":"Zhu","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117924_bib32","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s41388-017-0045-7","article-title":"Epidermal growth factor receptor (EGFR) and EGFRvIII in glioblastoma (GBM): signaling pathways and targeted therapies","volume":"37","author":"An","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.117924_bib33","first-page":"7094","article-title":"CHI3L1 as a prognostic biomarker and therapeutic target in glioma","volume":"25","author":"Zhou","year":"2024","journal-title":"Indian J. Manag. Sci."},{"key":"10.1016\/j.ejmech.2025.117924_bib34","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1158\/0008-5472.CAN-21-3629","article-title":"Chi3l1 is a modulator of glioma stem cell states and a therapeutic target in glioblastoma","volume":"83","author":"Guetta-Terrier","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117924_bib35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13024-025-00801-8","article-title":"Chitinase-3-like-1: a multifaceted player in neuroinflammation and degenerative pathologies with therapeutic implications","volume":"20","author":"Mwale","year":"2025","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ejmech.2025.117924_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-023-01131-9","article-title":"Significance of chitinase-3-like protein 1 in the pathogenesis of inflammatory diseases and cancer","volume":"56","author":"Yu","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejmech.2025.117924_bib37","first-page":"1","article-title":"Chitinase-3 like-protein-1 function and its role in diseases","volume":"5","author":"Zhao","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2025.117924_bib38","doi-asserted-by":"crossref","first-page":"39893","DOI":"10.1074\/jbc.M111.257451","article-title":"A complex of nuclear factor I-X3 and STAT3 regulates astrocyte and glioma migration through the secreted glycoprotein YKL-40","volume":"286","author":"Singh","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.117924_bib39","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.celrep.2013.07.032","article-title":"Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor \u03b12","volume":"4","author":"He","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2025.117924_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-023-01131-9","article-title":"Significance of chitinase-3-like protein 1 in the pathogenesis of inflammatory diseases and cancer","volume":"56","author":"Yu","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejmech.2025.117924_bib41","doi-asserted-by":"crossref","first-page":"330","DOI":"10.7150\/ijbs.37781","article-title":"G721-0282 inhibits cell growth and induces apoptosis in human osteosarcoma through down-regulation of the STAT3 pathway","volume":"16","author":"Park","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ejmech.2025.117924_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114520","article-title":"Multimodal study of CHI3L1 inhibition and its effect on angiogenesis, migration, immune response and refractive index of cellular structures in glioblastoma","volume":"161","author":"Rusak","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.117924_bib43","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1021\/acs.jmedchem.3c02255","article-title":"Structure-based discovery of high-affinity small molecule ligands and development of tool probes to study the role of Chitinase-3-Like protein 1","volume":"67","author":"Czestkowski","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117924_bib44","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.4110\/in.2021.21.e22","article-title":"Inhibition of Chitinase-3-like-1 by K284-6111 reduces atopic skin inflammation via repressing lactoferrin","volume":"21","author":"Jeon","year":"2021","journal-title":"Immune Netw"},{"key":"10.1016\/j.ejmech.2025.117924_bib45","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.celrep.2013.07.032","article-title":"Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor \u03b12","volume":"4","author":"He","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2025.117924_bib46","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.4110\/in.2021.21.e22","article-title":"Inhibition of Chitinase-3-like-1 by K284-6111 reduces atopic skin inflammation via repressing lactoferrin","volume":"21","author":"Jeon","year":"2021","journal-title":"Immune Netw"},{"key":"10.1016\/j.ejmech.2025.117924_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109877","article-title":"Inhibition of Chitinase-3-like-1 expression by K284 ameliorates lipopolysaccharide-induced acute liver injury through Down regulation of CXCL3","volume":"116","author":"Kim","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejmech.2025.117924_bib48","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s12974-020-02022-w","article-title":"K284-6111 alleviates memory impairment and neuroinflammation in Tg2576 mice by inhibition of Chitinase-3-like 1 regulating ERK-Dependent PTX3 pathway","volume":"17","author":"Ham","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ejmech.2025.117924_bib52","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1039\/D3RA08086B","article-title":"Lithocholic acid derivatives as potent modulators of the nuclear receptor ROR\u03b3t","volume":"14","author":"Abdel-Rahman","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2025.117924_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114520","article-title":"Multimodal study of CHI3L1 inhibition and its effect on angiogenesis, migration, immune response and refractive index of cellular structures in glioblastoma","volume":"161","author":"Rusak","year":"2023","journal-title":"Biomed. Pharmacother."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425006890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425006890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:55:26Z","timestamp":1776920126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425006890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":50,"alternative-id":["S0223523425006890"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117924","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lead optimization of a CHI3L1 inhibitor for Glioblastoma: Enhanced target engagement, pharmacokinetics, and efficacy in 3D spheroid models","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117924","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117924"}}